MElanoma Research Lymph Node Prediction Implementation National_001
(MERLIN_001 Trial)

Recruiting in Palo Alto (17 mi)

+8 other locations

Overseen byMichael E. Egger, MD, MPH

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: SkylineDx

No Placebo Group

Trial Summary

What is the purpose of this trial?

MERLIN_001 is a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and to determine its prognostic value for more accurate staging of SN-negative melanoma patients.

Research Team

Vernon K. Sondak, MD

Principal Investigator

Moffitt Cancer Center

Tina J. Hieken, MD

Principal Investigator

Mayo Clinic

Michael E. Egger, MD, MPH

Principal Investigator

University of Louisville

Eligibility Criteria

Inclusion Criteria

Newly diagnosed patients with invasive malignant melanoma of the skin (AJCC 8th edition staging guidelines) elected to undergo sentinel lymph node biopsy per the treating physician's recommendation.

Male or female, age ≥18 years.